SOURCE: Trend Exploration

July 09, 2010 16:30 ET

TRDX & Genesis Biopharma Announce Dr. Bahige Baroudy as Chief Science Officer to Lead Development of Potential Diabetic Neuropathy Cure

LONG ISLAND, NY--(Marketwire - July 9, 2010) -  SciMeDent Health Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces plans to appoint Dr. Bahige Baroudy of Genesis Biopharma to the equivalent role of Chief Science Officer at TRDX for the continued development of a potential cure for diabetic neuropathy.

Dr. Bahige Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Genesis Biopharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on "The Scientific American 50" list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.

Dr. Baroudy stated: "We are pleased that we have received the approval of Health Canada to proceed to Phase 1 clinical studies."

Dr. Jan Stahl, CEO of TRDX, commented: "We look forward to the work Dr. Baroudy will execute in bringing this potential cure to market."

About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information